SCHEMBL6284010

SCHEMBL6284010

COc1ccc(C(=O)CN2C(=O)N(C(=O)c3ccc4ccccc4c3)C(=O)C2(C)C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CBX7 O95931 2/20 0.46
CDYL2 Q8N8U2 2/20 0.46
CDYL Q9Y232 2/20 0.46
CDY1; CDY1B Q9Y6F8 2/20 0.46
NPC1 O15118 7/20 0.46
RAB9A P51151 7/20 0.43
CASP3 P42574 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
POLB P06746 2/20 0.42
ELANE P08246 1/20 0.42
CTSG P08311 1/20 0.42
PRTN3 P24158 1/20 0.42
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
KMT2A Q03164 2/20 0.40
PAX8 Q06710 1/20 0.40
MEN1 O00255 1/20 0.39
MGAM O43451 1/20 0.39
AMY1A P0DUB6 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6283097 0.91 CBX7 (0.42) CBX7CDYL2CDYLCDY1; CDY1BNPC1
SCHEMBL6285680 0.89 CBX7 (0.41) CBX7CDYL2CDYLCDY1; CDY1BNPC1
SCHEMBL6284006 0.85 ALDH1A1 (0.45) NPC1RAB9AELANEKMT2AMEN1
SCHEMBL6282090 0.84 KMT2A (0.46) CBX7CDYL2CDYLCDY1; CDY1BNPC1
SCHEMBL6285250 0.80 CBX7 (0.40) CBX7CDYL2CDYLCDY1; CDY1BNPC1
SCHEMBL6287762 0.77 BCHE (0.41) CBX7CDYL2CDYLCDY1; CDY1BNPC1
SCHEMBL6282978 0.76 DRD4 (0.43) CBX7CDYL2CDYLCDY1; CDY1BNPC1
SCHEMBL6285489 0.74 DRD4 (0.46) CBX7CDYL2CDYLCDY1; CDY1BNPC1
SCHEMBL6287615 0.73 BCHE (0.43) CBX7CDYL2CDYLCDY1; CDY1BNPC1
SCHEMBL6282913 0.73 KMT2A (0.46) CBX7CDYL2CDYLCDY1; CDY1BNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919365-B2 Imidazolidinedione derivatives and use thereof as drugs SENJU PHARMACEUTICAL CO., LTD. (JP) 2005-07-19 US disclosed
US-20040110811-A1 Novel imidazolidinedione derivatives and use thereof as drugs SENJU PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed
EP-1384715-A1 NOVEL IMIDAZOLIDINEDIONE DERIVATIVES AND USE THEREOF AS DRUGS Senju Pharmaceutical Co., Ltd. (JP) 2004-01-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110811-A1 Novel imidazolidinedione derivatives and use thereof as drugs CMA1, TPSD1, TPSB2 CBX7 2579/4885CDYL2 3565/4885CDYL 3427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.